CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD.

Chengdu Kanghua Biological Products Co., Ltd.

300841

CNE100003Y57

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
61.64 ^CNY	+1.18%		-3.72%	-20.51%

Apr. 29	Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024	CI
Apr. 23	Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024

April 28, 2024

Chengdu Kanghua Biological Products Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 20.00000000 for the year 2023, payable on 08 May 2024. Record date is 07 May 2024. Ex-date is 08 May 2024.

Latest news about Chengdu Kanghua Biological Products Co., Ltd.

Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024	Apr. 28	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Chengdu Kanghua Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 01	CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on January 23, 2024.	Apr. 01	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Chengdu Kanghua Biological Products Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Jan. 23	CI
Chengdu Kanghua Biological Products Co., Ltd. authorizes a Buyback Plan.	Jan. 21	CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax	Jan. 08	MT
Hillevax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China	Jan. 08	CI
Chengdu Kanghua Biological Products Co., Ltd.(SZSE:300841) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Chengdu Kanghua Biological Products Co., Ltd.(SZSE:300841) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) completed the acquisition of 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao.	Nov. 20	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) agreed to acquire 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao for approximately CNY550 million.	23-08-23	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Certain A Shares of Chengdu Kanghua Biological Products Co., Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2023.	23-06-15	CI
Chengdu Kanghua Biological Products Co., Ltd. Approves Cash Dividend for 2022, Payable on 24 May 2023	23-04-28	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Chengdu Kanghua Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year of 2022	23-03-30	CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 29, 2021.	22-10-28	CI
Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback announced on October 29, 2021, has expired with 901,775 shares, representing 0.67% for CNY 123.10 million.	22-10-26	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 29, 2021.	22-10-10	CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 29, 2021.	22-07-04	CI

Chart Chengdu Kanghua Biological Products Co., Ltd.

Duration

Period

Chart Chengdu Kanghua Biological Products Co., Ltd.

More charts

Company Profile

Chengdu Kanghua Biological Products Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of vaccine products. The Company's main products are Rabies Vaccine (human diploid cell) for Human Use, Freeze-dried and Group ACYW135 Meningococcal Polysaccharide Vaccine. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chengdu Kanghua Biological Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

61.64 CNY

Average target price

94.12 CNY

Spread / Average Target

+52.70%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD.	-20.51%	1.13B
CSL LIMITED	-2.63%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals